Strategies for purging CD96(+) stem cells in vitro and in vivo: New avenues for autologous stem cell transplantation in acute myeloid leukemia.
Strategies for purging CD96(+) stem cells in vitro and in vivo: New avenues for autologous stem cell transplantation in acute myeloid leukemia.
复制标题
DOI：
10.4161/onci.24500
复制
发表时间：
2013-06-01
期刊：
影响因子：
7.2
通讯作者：
Gramatzki M
中科院分区：
文献类型：
--
作者：
Staudinger M;Humpe A;Gramatzki M
接受化疗的急性髓性白血病（AML）患者中白血病干细胞（LSC）的持续存在可能是导致高复发率的原因。通过CD 96特异性单克隆抗体选择性消除CD 96 + AML-LSC可能是一种有前途的治疗方法，并恢复自体造血祖细胞移植。
The persistence of leukemic stem cells (LSCs) in acute myeloid leukemia (AML) patients receiving chemotherapy may be responsible for the high frequency of relapse. The selective elimination of CD96+ AML-LSCs by means of CD96-specific monoclonal antibodies may be a promising therapeutic approach and revitalize autologous hematopoietic progenitor cell transplantation.